Shionogi Entered into a Commercialization Agreement with Susmed for Digital Therapeutic App to Treat Insomnia
Shots:
- Susmed to receive ~ $40.92M including up front and development milestones, upon closure of the agreement & is eligible to receive royalties on product sales. Additionally, both companies will provide new healthcare solutions, including joint development of digital therapeutic apps
- Under the terms of the agreement, Shionogi will acquire the exclusive marketing rights for Digital Therapeutic App in Japan
- The app is currently under development by Susmed. In a P-III trial, the app showed a significant improvement in the Athens insomnia scale (an index of insomnia severity). Susmed plans to submit an NDA for the digital therapeutic app for insomnia, based on the results from the P-III trial
Ref: Shionogi | Image: Shionogi
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com